CLOSEOUT LETTER
Rcba Nutraceuticals LLC MARCS-CMS 486978 —
- Recipient:
- Rcba Nutraceuticals LLC
United States
- Issuing Office:
United States
|
5001 Campus Drive |
|
September 12, 2017
Ronnie Coleman
Ronnie Coleman Signature Series
Rcba Nutraceuticals, LLC
2041 High Ridge Rd
Boynton Beach, Florida 33426
Dear Mr. Coleman:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter #486978, issued March 7, 2016. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Latasha A. Robinson, M.S.
Branch Chief
Dietary Supplement and Labeling Assessment Branch
Division of Enforcement
Office of Compliance
Center for Food Safety and Applied Nutrition